SCHEMBL831307

SCHEMBL831307

COc1ccc(CS(=O)(=O)c2cc3c(Br)cc(Br)cc3[nH]c2=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.41
PLCG1 P19174 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
APLNR P35414 2/20 0.37
THRB P10828 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
POLB P06746 1/20 0.35
CRBN Q96SW2 1/20 0.35
ADORA2B P29275 1/20 0.35
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
GRK2 P25098 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MMP1 P03956 1/20 0.35
MMP13 P45452 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831312 0.85 RHEB (0.37) PTGS1PTGS2KDM4EEGLN1CA12
SCHEMBL829941 0.81 GFER (0.39) THRBKDM4EPOLB
SCHEMBL830013 0.80 PIM1 (0.39) PTGS2CDK4CCND1
SCHEMBL830014 0.80 PIM1 (0.39) PTGS2CDK4CCND1
SCHEMBL830281 0.80 BRD4 (0.47) THRBPOLB
SCHEMBL831859 0.78 PIM1 (0.42) PTGS2CDK4CCND1
SCHEMBL830383 0.78 PIM1 (0.42) PTGS2CDK4CCND1
SCHEMBL830382 0.78 PIM1 (0.42) PTGS2CDK4CCND1
SCHEMBL830861 0.78 S100A9 (0.35) CA12CA1CA2
SCHEMBL831360 0.77 PLCG1 (0.36) PLCG1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP disclosed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 PARK7 4121/4885PLCG1 3619/4885PTGS1 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.